Fig. 4

Effect on fractional sodium excretion (FENa) and brain natriuretic peptide (BNP). The bumetanide plus placebo group is shown in blue (control group), and the bumetanide plus chlorthalidone group is shown in red (intervention group). A Analysis of FENA revealed that during the first week after the intervention, the bumetanide plus chlorthalidone group showed a decrease in FENA from 0.78 (95% CI, 0.35 to 1.22) to 0.59 (95% CI, -0.62 to 1.81) without intragroup statistical significance (p = 0.104), while the bumetanide plus placebo group had a change from baseline to day 30 of -0.34 (95% CI, -2.2 to -1.51; p = 0.605). B At the start of follow-up, the bumetanide plus placebo group showed an increase in BNP on Day 7 of 33.6 (95% CI, -61.5 to 128.8 pg/dL) and on Day 30 of 213.5 (95% CI, -143.4 to -570.5 pg/dL) without statistical significance (p = 0.175). The intervention group showed a decrease on Day 7 of -39.3 (95% CI, 19.3 to -25 pg/dL) and on Day 30 of -0.64 (95% CI, -78.7 to 77.4 pg/dL) without a significant difference (p = 0.221). Similarly, intergroup analysis did not reveal any significant differences